Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

Erica L. Mayer; Amylou C. Dueck; Miguel Martín; Gábor Rubovszky; Harold J. Burstein; M. Bellet-Ezquerra; Kathy D. Miller; Nicholas Zdenkowski; Eric P. Winer; Georg Pfeiler; Matthew P. Goetz; Manuel Ruíz‐Borrego; D. Mark Anderson; Zbigniew Nowecki; Sibylle Loibl; Stacy Moulder; Alistair Ring; Florian Fitzal; Tiffany A. Traina; Arlene Chan; Hope S. Rugo; Julie Lemieux; Fernando Henao; Alan P. Lyss; Silvia Antolín; Antonio C. Wolff; Marcus Vetter; Daniel Egle; Patrick G. Morris; Eleftherios P. Mamounas; Miguel Gil‐Gil; Aleix Prat; Hannes Fohler; Otto Metzger; Magdalena Schwarz; Carter DuFrane; Debora Fumagalli; Kathy Puyana Theall; Dongrui R. Lu; Cynthia Huang Bartlett; María Koehler; Christian Fesl; Angela DeMichele; Michael Gnant

doi:10.1016/s1470-2045(20)30642-2

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

Erica L. Mayer(Dana-Farber Cancer Institute), Amylou C. Dueck(WinnMed), Miguel Martín(Hospital General Universitario Gregorio Marañón), Gábor Rubovszky(National Institute of Oncology), Harold J. Burstein(Dana-Farber Cancer Institute), M. Bellet-Ezquerra(Vall d'Hebron Hospital Universitari), Kathy D. Miller(Indiana University Health), Nicholas Zdenkowski(Lake Macquarie Private Hospital), Eric P. Winer(Dana-Farber Cancer Institute), Georg Pfeiler(Medical University of Vienna), Matthew P. Goetz(Mayo Clinic in Arizona), Manuel Ruíz‐Borrego(GEICAM – Spanish Breast Cancer Group), D. Mark Anderson(Regions Hospital), Zbigniew Nowecki(The Maria Sklodowska-Curie National Research Institute of Oncology), Sibylle Loibl(German Breast group), Stacy Moulder(The University of Texas MD Anderson Cancer Center), Alistair Ring(Royal Marsden NHS Foundation Trust), Florian Fitzal(Medical University of Vienna), Tiffany A. Traina(Memorial Sloan Kettering Cancer Center), Arlene Chan(Hollywood Private Hospital), Hope S. Rugo(University of California, San Francisco), Julie Lemieux(Université Laval), Fernando Henao(Hospital Universitario Virgen Macarena), Alan P. Lyss(Missouri Baptist Medical Center), Silvia Antolín(Universidade da Coruña), Antonio C. Wolff(Johns Hopkins University), Marcus Vetter(University Hospital of Basel), Daniel Egle(Innsbruck Medical University), Patrick G. Morris(Cancer Trials Ireland), Eleftherios P. Mamounas(Orlando Health), Miguel Gil‐Gil(Institut Català d'Oncologia), Aleix Prat(Hospital Clínic de Barcelona), Hannes Fohler(Austrian Breast & Colorectal Cancer Study Group), Otto Metzger(Dana-Farber Cancer Institute), Magdalena Schwarz(Austrian Breast & Colorectal Cancer Study Group), Carter DuFrane(Alliance Foundation Trials), Debora Fumagalli(Breast International Group), Kathy Puyana Theall(Pfizer (United States)), Dongrui R. Lu(Pfizer (United States)), Cynthia Huang Bartlett(Pfizer (United States)), María Koehler(Pfizer (United States)), Christian Fesl(Austrian Breast & Colorectal Cancer Study Group), Angela DeMichele(Penn Center for AIDS Research), Michael Gnant(Medical University of Vienna)

The Lancet Oncology

January 18, 2021

10.1016/s1470-2045(20)30642-2

Cited by 255

Abstract

Related Papers

No related papers found

Powered by citation graph analysis